{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 32 of 122', 'On the day after each study site visit, site staff will contact the subject or parent/caregiver by', 'telephone to perform the following:', 'Inquire if any adverse events occurred (including allergy symptoms, GI symptoms,', 'and exposure to food allergen).', 'Provide guidance in managing adverse events.', 'Inquire about compliance with AR101 dosing.', '5.2.4.1', 'Initial Dose-Escalation Procedures', 'Initial dose-escalation procedures are listed in the schedule of activities in Appendix 4.', 'Subjects may have clear liquids or flavored gelatin during the dosing procedures.', 'Day 1', 'Subjects will be required to discontinue antihistamines 5 half-lives of the medication before', 'the first day of dose escalation.', 'AR101 will be administered in 5 increasing doses in a stepwise manner in 20- to 30-minute', 'intervals as tolerated. The 5 doses and cumulative dose of peanut protein to be consumed on', 'day 1 are shown in Table 2.', 'Table 2: AR101 Single Doses and Cumulative Dose on Day 1', 'Dose Number', 'AR101 Dose (mg peanut protein)', 'Cumulative Dose (mg peanut protein)', '1', '0.5', '0.5', '2', '1', '1.5', '3', '1.5', '3', '4', '3', '6', '5', '6', '12', 'The time points for AR101 dosing and assessments of vital signs and allergic reaction are', 'provided in Table 3. Subjects who develop moderate or dose-limiting symptoms anytime at', '< 3 mg doses of AR101, severe symptoms at any dose (including 6 mg), or use rescue', 'medications (except < 2 doses of antihistamines, Section 8.5.3.1) will stop dose escalation', 'and discontinue early from the study (Section 5.3).']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 33 of 122', 'Table 3: Initial Dose-Escalation Day 1 Procedures', 'AR101 Dose (Timing)', 'Administer', 'Blood', 'Heart', 'Assess Allergic', 'Time Point', 'AR101', 'Pressure', 'Rate', 'Temp', 'Reaction', 'Predose', 'X', 'X', 'X', '0.5 mg', 'X', '15-30 min postdose', 'X', 'X', 'X', '1 mg (20-30 min after previous dose) [1]', 'X', '15-30 min postdose', 'X', 'X', '1.5 mg (20-30 min after previous dose) [1]', 'X', '15-30 min postdose', 'X', 'X', 'X', '3 mg (20-30 min after previous dose) [1]', 'X', '15-30 min postdose', 'X', 'X', 'X', '6 mg (20-30 min after previous dose)', 'X', '15-30 min postdose', 'X', 'X', 'X', 'Every 30 min until at least 90 min after', 'X', 'X', 'X', 'last dose or end of observation per', 'allergy symptoms [2]', '[1] If the previous dose was tolerated (Section 8.5.1.2). If the subject has moderate or dose-limiting', 'symptoms anytime at < 3 mg, severe symptoms at any dose (including 6 mg), or uses rescue medications', '(except VI 2 doses of antihistamines, Section 8.5.3.1), stop dose escalation and discontinue the subject', 'early from the study. If at least 3 mg is tolerated, the subject will return for a confirmatory 3 mg dose on', 'day 2.', '[2] The length of observation is based on signs/symptoms of allergic reaction per Section 8.5.1.', 'Min, minutes; temp, temperature.', 'Day 2', 'Subjects who tolerate at least 3 mg of AR101 on day 1 will return to the study site on day 2', 'to receive a single confirmatory 3 mg dose under direct observation. Day 2 should be the', 'next consecutive day after day 1. If circumstances (eg, an intercurrent illness) create a safety', 'risk, day 2 may be delayed up to 7 days after day 1. Subjects who tolerate the 3 mg', 'confirmatory dose with no or mild symptoms that are not dose-limiting will receive an', 'adequate supply of study product to continue daily dosing at home at 3 mg/day in the', 'up-dosing period (Section 5.2.4.2).', 'Subjects who are unable to return to the study site < 7 days after day 1 for day 2 procedures', 'or who develop moderate or severe symptoms after receiving the 3 mg dose on day 2, or use', 'rescue medications (except < 2 doses of antihistamines, Section 8.5.3.1), will stop AR101', 'treatment and discontinue early from the study (Section 5.3).']\n\n###\n\n", "completion": "END"}